donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
06833 Sinco Pharmaceuticals
1.200
-0.020-1.64%
YOY
Do not show
Hide blank lines
(FY)2021/12/31(Q6)2021/06/30(FY)2020/12/31(Q6)2020/06/30
Turnover
-1.26% 2.02B 33.12% 847.04M 74.24% 2.05B 18.84% 636.31M
Operating income
-1.26% 2.02B 33.12% 847.04M 74.24% 2.05B 18.84% 636.31M
Cost of sales
6.58% -1.66B -30.66% -689.52M -85.66% -1.78B -18.72% -527.73M
Operating expenses
6.58% -1.66B -30.66% -689.52M -85.66% -1.78B -18.72% -527.73M
Gross profit
33.28% 364.95M 45.08% 157.53M 24.55% 273.83M 19.41% 108.58M
Selling expenses
-17.3% -105.38M 43.14% -34.87M 21.57% -89.84M -37.91% -61.33M
Administrative expenses
-62.76% -66M 13.5% -17.43M 11.47% -40.55M 4.11% -20.15M
Impairment and provision
-383.44% -856K -98.32% 38K 123.74% 302K 140.13% 2.26M
-Other impairment is provision
-383.44% -856K -98.32% 38K 123.74% 302K 140.13% 2.26M
Special items of operating profit
278.75% 3.83M -38.39% 1.24M -78.68% 1.01M -83.42% 2.02M
Operating profit
35.78% 196.55M 239.41% 106.51M 129.83% 144.75M -1.94% 31.38M
Financing cost
-231.52% -29.16M -1120.16% -14.83M 56.07% -8.8M 88.1% -1.22M
Earning before tax
23.12% 167.39M 203.93% 91.68M 216.51% 135.96M 38.44% 30.17M
Tax
-81.3% -32.3M -817.54% -16.4M 8.18% -17.82M 134.72% 2.29M
After-tax profit from continuing operations
14.34% 135.08M 131.98% 75.28M 401.64% 118.14M 113.42% 32.45M
Earning after tax
14.34% 135.08M 131.98% 75.28M 401.64% 118.14M 113.42% 32.45M
Profit attributable to shareholders
14.34% 135.08M 131.98% 75.28M 401.6% 118.14M 113.4% 32.45M
Basic earnings per share
11.43% 0.078 131.58% 0.044 400% 0.07 111.11% 0.019
Diluted earnings per share
11.43% 0.078 131.58% 0.044 400% 0.07 111.11% 0.019
Currency Unit
CNYCNYCNYCNY
Accounting Standards
IASIASIASIAS
Audit Opinions
Unqualified Opinion--Unqualified Opinion--
Auditor
Ernst & Young accounting firm--Ernst & Young accounting firm--

Q6, Q9, and FY are cumulative quarterly reports: Q6 is the interim report; Q9 is third quarter report; FY is the annual report.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
Xingke Rong Pharmaceutical Holdings Co., Ltd. mainly provides marketing, promotion and channel management (MPCM) services in the pharmaceutical industry of the people's Republic of China. The company provides comprehensive MPCM services to small and medium-sized overseas pharmaceutical manufacturers that do not have independent marketing and promotion capabilities in China. Its main product is human serum albumin injection. The product is a human serum albumin produced by Octapharma for the treatment of hypovolemic and hypovolemic shock, abnormally high intracranial pressure, edema and ascites, as well as the prevention and treatment of hypoalbuminemia and neonatal hyperbilirubinemia. In addition, its products include Ankexin, McDonnell, Elsaif, Tate and Torot and so on.
CEO: Xiangbin Huang
Market: Hong Kong motherboard
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...